Accepted Manuscript

Predicting 15-year Mortality in Adults with Congenital Heart Disease Using Disease Severity and Functional Indices

Fouke Ombelet, MSc, RN, Eva Goossens, PhD, RN, Silke Apers, PhD, RM, Werner Budts, MD, PhD, Marc Gewillig, MD, PhD, Philip Moons, PhD, RN

PII: S0828-282X(19)30291-0

DOI: <https://doi.org/10.1016/j.cjca.2019.04.018>

Reference: CJCA 3245

To appear in: *Canadian Journal of Cardiology*

Received Date: 21 January 2019

Revised Date: 16 April 2019

Accepted Date: 23 April 2019

Please cite this article as: Ombelet F, Goossens E, Apers S, Budts W, Gewillig M, Moons P, Predicting 15-year Mortality in Adults with Congenital Heart Disease Using Disease Severity and Functional Indices, *Canadian Journal of Cardiology* (2019), doi: <https://doi.org/10.1016/j.cjca.2019.04.018>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Predicting 15-year Mortality in Adults with Congenital Heart Disease Using Disease Severity and Functional Indices

Short title: Predicting 15-year Mortality in Adult CHD

Total word count: 4912

Fouke Ombelet, MSc, RN,^a Eva Goossens, PhD, RN,^{a,b} Silke Apers, PhD, RM,^a Werner Budts, MD, PhD,^{c,d} Marc Gewillig, MD, PhD,^{c,e} Philip Moons PhD, RN^{a,f,g,*}

^aKU Leuven Department of Public Health and Primary Care, KU Leuven – University of Leuven, Leuven, Belgium

^bResearch Foundation Flanders (FWO), Brussels, Belgium

^cKU Leuven Department of Cardiovascular Sciences, KU Leuven – University of Leuven, Leuven, Belgium

^dUniversity Hospitals Leuven, Division of Congenital and Structural Cardiology, Leuven, Belgium

^eUniversity Hospitals Leuven, Department of Pediatric Cardiology, Leuven, Belgium

^fInstitute of Health and Care Sciences, University of Gothenburg, Gothenburg, Sweden

^gDepartment of Pediatrics and Child Health, University of Cape Town, Cape Town, South Africa

***Correspondence:** Philip Moons, Kapucijnenvoer 35 box 7001, B-3000 Leuven, Belgium

Tel: +32-16-373315; Fax: +32-16-336970; E-mail: philip.moons@kuleuven.be

Brief Summary

Mortality risk algorithms are resource-intensive for use in daily clinical practice. Disease severity and functional indices are already widely used in patients with congenital heart disease. In this head-to-head comparison of five disease severity and functional indices in 629 adult CHD patients, the CHDFI showed the highest accuracy in predicting long-term all-cause and cardiac mortality. The CHDFI may aid physicians in determining patients at risk and consequently patients that require specialized follow-up.

Abstract (250 words)

Background: Disease severity and functional indices are widely used for risk stratification of patients with congenital heart disease (CHD). The predictive value of these classification systems for assessing long-term mortality is unknown. We aimed to determine and compare the predictive value of disease severity and functional indices for 15-year mortality in adults with CHD.

Methods: Between 2000 and 2002, we categorized 629 patients with CHD (median age=24y; 60% men) on five indices: disease complexity scores based on criteria of Task Force 1 of the 32nd Bethesda Conference; Disease Severity Index; New York Heart Association (NYHA) functional class; Ability Index; and Congenital Heart Disease Functional Index (CHDFI). Harrell's C-index was calculated for each classification system through Cox hazard regression analysis to evaluate their performance on predicting all-cause and cardiac mortality over the subsequent 15 years.

Results: Over the 15-year follow-up period, 40 patients died, resulting in a mortality rate of 4.56 per 1,000 person-years. The CHDFI showed the highest discrimination ability for all-cause (C-index=0.74; $p<0.001$) and cardiac mortality (C-index=0.76; $p<0.001$). The C-index for the other classifications ranged from 0.58-0.71 for all-cause and 0.55-0.67 for cardiac mortality. The CHDFI showed statistical superiority towards the Disease Severity Index ($p<0.01$).

Conclusions: These results suggest that the Task Force 1 of the 32nd Bethesda Conference, the NYHA functional class, the Ability Index and the CHDFI could aid in predicting long-term mortality. The CHDFI showed to have the highest discrimination ability and emphasizes the importance to integrate both anatomical and physiological variables to predict long-term mortality.

Introduction

Compared to the general population, patients with congenital heart disease (CHD) have a higher mortality risk, shown by a Standardized Mortality Ratio (SMR) of 2.29¹. To identify patients with CHD who require the most careful monitoring, clinicians can perform risk stratifications. Mortality risk algorithms or classification schemes have been developed and tested, but currently appear to exist only for pediatric patients²⁻⁴; specific surgical populations, like patients with Fontan circulation⁵; or patients following heart transplantation⁶, or require data that are not always readily available⁷. Overall, the use of resource-, time-, and cost-intensive algorithms in clinical practice is often impractical.

To the best of our knowledge, to date no simple algorithm exists that reliably predicts mortality risk in adults with CHD. This may be one reason why risk stratification is often done based on the level of disease complexity, as defined by the Task Force 1 of the 32nd Bethesda conference⁸. This classification system categorizes patients as having either simple, moderate, or severely complex heart lesions. This instrument was developed based on expert consensus. However, it does not account for disease evolution and complications, despite high incidence rates of complications in this population⁹. Besides the Bethesda disease complexity classification, there are several other disease severity or functional indices available to categorize patients with CHD, such as the New York Heart Association functional class (NYHA)¹⁰, the Ability Index¹¹, the Disease Severity Index¹², and the Congenital Heart Disease Functional Index (CHDFI)¹³.

Previous studies demonstrated differences in mortality risks between the classes of the Bethesda disease complexity scheme. Patients with a severely complex heart defect have a higher SMR as compared to the general population and patients with a simple lesion^{1, 14, 15}. The NYHA functional class also relates to mortality, having a higher hazard ratio (HR) when comparing patients in higher NYHA classes to those in Class I¹⁶. The other classification

systems, however, have not yet been scrutinized for their value in identifying patients at risk for premature mortality. Furthermore, a direct comparison of these classification systems has not been done. We therefore aimed (i) to determine the predictive value of different disease severity and functional indices for 15-year all-cause and cardiac mortality, and (ii) to determine whether one classification is superior to another in detecting adults with CHD at higher risk for mortality.

Material and methods

Study population and setting

We conducted a cohort study in adults with CHD over 15 years. Between 2000 and 2002, 629 patients were included in a previously conducted cross-sectional study on quality of life and perceived health status^{13, 17, 18}. This study included a consecutive series of patients who visited the adult CHD outpatient clinic of the University Hospitals Leuven, Belgium. Patients were eligible for this initial study if they met the following inclusion criteria: diagnosed with a congenital heart defect, as defined by Mitchell¹⁹; being ≥ 18 years of age; literate; and Dutch-speaking. All patients gave oral informed consent. Patients were excluded if it was their first outpatient visit at this clinic because it is our policy not to approach patients for research project at their first encounters to build up a trusting relationship first, if they had learning disabilities, or if they were referred for or were in follow-up after closure of an atrial septal defect or patent foramen ovale following cryptogenic stroke¹³.

The treating cardiologist (WB) scored each individual patient on five different scales for functional status or disease severity at study inclusion¹³. In December 2018, data on mortality was collected retrospectively.

Variables and measurements

Disease severity and functional indices

The five classification systems used in this study were as follows: Bethesda disease complexity classification⁸; NYHA functional class¹⁰; Ability Index¹¹; Disease Severity Index¹²; and CHDFI¹³. The Bethesda disease complexity classification categorizes patients into three groups: simple, moderate, and severely complex congenital heart defects based on the anatomical complexity⁸. The NYHA has four functional classes pertaining to the patient's day-to-day level of functioning and experienced symptoms¹⁰. The Ability Index scores patients on their capacity to work, capacity to be active, and ability to go through uncomplicated pregnancies (if applicable). It assigns patients to four classes¹¹. The Disease Severity Index compiles information on the patient's history of surgical and/or catheter-based interventions and whether they have persistent cyanosis, allocating patients to one of three categories¹². Finally, the CHDFI has five categories, comprising different elements of the patient's status: surgical history, clinical status, functional capacity, and current frequency of follow-up based on disease complexity or on the physician's professional opinion¹³. More details on these scales are presented in Supplementary Table 1.

Mortality

The date and cause of death were obtained from the hospitals' electronic medical records. We classified the cause of death as either cardiac or non-cardiac. Cardiac death included: deaths caused by acute myocardial infarction, sudden cardiac death, heart failure, stroke, cardiovascular procedure (pre- or post-procedure), cardiovascular hemorrhage, or other cardiovascular causes, such as pulmonary embolism. Categories for non-cardiac death included: deaths caused by pulmonary, renal, gastro-intestinal, hepatobiliary, or pancreatic disease; infection; inflammation; neurological issues; non-cardiovascular- or non-stroke-related hemorrhage, non-cardiovascular procedure or surgery; trauma; cancer; or suicide²⁰. For patients presumed alive, we defined the date at which they were last seen alive as the date

of the patient's last in- or outpatient visit in our hospital or affiliated hospitals or the date of any contact by telephone with a member of the healthcare staff. This resulted in three possible endpoints: (i) patient deceased, date of death is the endpoint; (ii) patient was last seen alive before the end of the 15 year interval and the patient was right censored; (iii) patient was last seen alive after the end of the 15 year interval and the study end point is at 15 years after initial study inclusion. Data at baseline was collected as part of a previous study as mentioned for which approval of the ethics committee was previously obtained. Data on mortality was collected retrospectively via the hospital medical records, for which additional approval was acquired by the institutional review board.

Statistical analysis

Categorical data were expressed as absolute numbers and proportions. Age was the only continuous variable, presented as the median with interquartile range (IQR) because of heteroscedasticity of the data. We calculated Kaplan-Meier survival curves and computed Harrell's C-index (C-index) through a Cox Proportional Regression analysis to evaluate prediction models for accuracy²¹. On the basis of the work of Hosmer and Lemeshow²², we categorized models using the following cut-offs: a C-index ≥ 0.90 was considered to be an outstanding model; a C-index between 0.80-0.89 represented an excellent model; a C-index between 0.70-0.79 indicated a good model; and a C-index <0.70 was considered to represent a poor model. C-indices were compared pair-wise using a nonparametric approach developed for right-censored survival data²³. We used IBM SPSS version 25 for Windows (Armonk NY: IBM Corp.) and R version 3.4.3²⁴. A significance level of $p < 0.05$ was used, and all tests were two-sided. Bonferroni correction was used to correct for multiple testing when comparing the C-indices of the different classifications, by dividing 0.05 by 20 and obtaining a p value of 0.0025.

Results

Study population

Median age of patients at time of inclusion was 24 years (IQR 20-29 years), and 60% were men. Median duration of follow-up was 15 years, with 82% reaching the maximum duration of 15 years. The most common primary diagnosis was Tetralogy of Fallot, followed by ventricle septal defect and coarctation of the aorta. More than half of the study population had a history of surgical intervention(s), with or without catheter-based intervention(s). Twenty-six patients had a genetic syndrome known to be associated with CHD (Table 1).

PLEASE INSERT TABLE 1 ABOUT HERE

Disease severity and functional indices

In our sample of 629 patients, 26% had a simple CHD, 58% a moderately complex CHD, and 16% a severely complex heart defect, as determined by the Bethesda disease complexity classification (Figure 1, bars). The largest group of patients (81%) was categorized as Class I in the NYHA classification scheme (i.e., “living without limitation of physical activity”). For the Ability Index, 83% of patients were assigned to Grade 1, which corresponded to having a normal life (e.g., full-time work or school). For the Disease Severity Index, 64% of patients were categorized as low disease severity. For the CHDFI, 57% of patients were categorized as Class 3 (Figure 1).

PLEASE INSERT FIGURE 1 ABOUT HERE

Mortality

A total of 8,764 person-years have been observed in this study. Forty patients died (6%) over the 15 years of follow-up, corresponding to a mortality rate of 4.56 per 1,000 person-years. Median age at time of death was 36 years (IQR 28-43.75 years). The cause of death was

available from medical records in 32 patients; 26 (81%) died from a cardiac cause (Supplementary Table 2). Nine (28%) died from sudden cardiac death, 7 (22%) from complications of a cardiovascular surgical procedure, 6 (19%) from heart failure, 1 (3%) had a cardiovascular hemorrhage, 1 (3%) died from an acute myocardial infarction, 1 (3%) died from Eisenmenger's syndrome, and 1 (3%) from complications related to arrhythmia. Six patients (19%) died from non-cardiac-related causes: 2 suicides, 2 deaths due to malignancy, 1 death after intracranial bleed and 1 related to fatal injuries associated with a traffic accident. Supplementary Table 2 lists the causes of death, stratified by type of heart defect.

Probability of survival stratified by disease severity and functional indices

The probability of survival over a period of 15 years was 82% for patients with a severely complex heart defect, as operationalized using the Bethesda classification, compared to 95% in patients with a moderately complex defect and 97% in patients with a simple heart defect (Figure 1). The findings as presented in Figure 1 and 2 show that the proportion of deceased patients increases with increasingly severe categories for all five classification systems.

Kaplan-Meier survival curves were plotted in Figure 2. Log rank tests demonstrated that the mortality curves were significantly different across the diverse categories of the respective classification systems, for all-cause and cardiac mortality with an exception for the Disease Severity Index concerning cardiac mortality.

PLEASE INSERT FIGURE 2 ABOUT HERE

The discriminating performance of each classification system in predicting mortality was assessed using Harrell's C-indices. The CHDFI produced the highest C-index, for both all-cause mortality (0.74; $p < 0.001$) and cardiac mortality (0.76; $p < 0.01$) (Table 2). Since these

C-indices for the CHDFI exceeded the cut-off of 0.70 as proposed by Hosmer and Lemeshow²², the CHDFI represented a good model fit in mortality prediction.

We statistically compared the C-indices of the different classification systems. The C-index of the CHDFI was significantly higher than the C-index of the Disease Severity Index for all-cause and cardiac mortality. The differences between the other C-indices did not reach statistical significance.

PLEASE INSERT TABLE 2 ABOUT HERE

Discussion

To the best of our knowledge, the present study is the first to directly compare five disease severity and functional classification systems with the purpose of identifying a quick tool for mortality prediction in adults with CHD. Previous research evaluated only the predictive value of two indices: the Bethesda disease complexity classification^{1, 14, 15, 25-27} and the NYHA functional class^{1, 16, 26, 28}, separately. As expected in these studies, patients in higher classes showed higher mortality. Also, as compared to mild heart defects, the moderate and complex heart lesions had HRs of 1.3-1.7 and 5.3-5.9, respectively^{15, 27}. For the NYHA, the HRs for mortality increased with increasing classes (2.78-2.9)^{26, 28}. Although direct comparisons between our results and the results of these studies are not possible, they do show similar trends.

We found that all scales significantly predicted all-cause and cardiac mortality, with the exception of the Disease Severity Index. The CHDFI had the highest C-index suggesting the best capacity to detect adults with CHD at higher risk for all-cause and cardiac mortality. This index outperformed the other classification systems in accurately predicting mortality. The CHDFI was the only classification system that had AUCs above 0.70 for both all-cause

and cardiac mortality. Hence, using the criteria of Hosmer and Lemeshow²², CHDFI served as a good prediction model. Another remarkable characteristic of the CHDFI was that in our study no patient in Class 1 died and only one patient in Class 2, which in this study resulted in a negative predictive value (NPV) of 100% when using Class 3 as a cut-off. This suggests that the CHDFI is highly satisfactory for predicting non-events.

The higher C-index of the CHDFI can be explained by some specific characteristics of this scale. First, the CHDFI captures the current state of the patient's condition, and therefore gives a contemporary view on the status of the patient. Other classification systems, such as the Bethesda classification or the Disease Severity Index, do not change over time, irrespective worsening of the patient's health status. Second, the CHDFI comprises five categories, whereas the other classification systems have three to four classes. This contributes to a higher responsiveness and the ability to capture more subtle differences between patients. Third, the CHDFI integrates scores across different functional domains that can more comprehensively capture the patient's true status. It reflects surgical history, functionality, required frequency of follow-up, sports participation allowed, and presence of cyanosis¹³. Therefore, the CHDFI is likely more fine-tuned to peer into the patient's overall condition than, for instance, the Bethesda disease complexity classification, which may only provide a restricted look, missing important aspects besides anatomical complexity. The refined capacity of the CHDFI likely contributed to its robust predictive value for mortality. The recently proposed adult congenital heart disease anatomic and physiological (ACHD AP) classification system, presented by the American Heart Association²⁹, supports the need for a more fine-tuned tool that captures both anatomic and physiological aspects and encompasses the fluctuations in the patient's health status. Obviously, this ACHD AP score needs to undergo validation tests and requires an investigation of its predictive characteristics.

This study can serve as a proof of concept for using functional indices for the purpose of predicting long-term mortality in adults with CHD. The CHDFI might be a useful tool that can be easily implemented in daily clinical practice. It gives a quick overview of the patient's condition, while at the same time providing a good prediction of mortality. Our study suggests that patients in CHDFI Classes 4 or 5 warrant close monitoring of disease progress and identification of specific risk factors for mortality. By implication, patients in Class 3 of the CHDFI may require more in-depth risk assessment, specifically assessing whether genetic syndromes, ventricular dysfunction, ventricular overload, pulmonary arterial hypertension, aneurysms, or ischemic heart disease might be present¹⁴. Given the absence of mortality in patients in Class 1 and 2 in our study, patients in these classes might not be at higher risk for mortality as compared to the general population, and therefore may not need an in-depth risk assessment for mortality. As the current healthcare system is characterized by a shortage of staff and resources, and CHD is characterized by increasing costs, clinicians and policymakers may also be interested in identifying patients who do not require specialized or frequent follow-up^{30, 31}. The CHDFI may be an appropriate tool to identify such patients, although more research is required to draw firm conclusions on the specificity of the CHDFI.

Methodological considerations

This study had several strengths. It was the first direct comparison of the predictive value of five disease severity and functional indices for long-term mortality. Since mortality in Belgium is comparable to that in other countries, this cohort was representative of patients in follow-up in adult CHD centers in other western countries³². A 15-year follow-up made it possible to compare these classification systems for their ability to predict long-term mortality. Furthermore, included patients were classified by a single cardiologist with expertise in adult CHD, avoiding the possibility of interrater biases. This, however, also entails the absence of data on interrater reliability of these five indices.

However, there are also some methodological limitations that warrant caution when generalizing our results to other situations. First, we investigated only the predictive value of the indices and scales with respect to mortality. It would be valuable to evaluate the classification systems in relation to the development of long-term morbidities. For instance, the NYHA functional class and the Ability Index are able to differentiate among patients with and without heart failure³³. It is, however, not known if they also can predict the development of heart failure. Second, 20% of the deceased patients had no information on the cause of death, complicating the distinction between cardiac mortality and non-cardiac mortality in our study. However, from a patient's perspective, this distinction is trivial. Third, this study may have been underpowered to find statistical significant differences between the five scales due to a low number of deceased patients for some classes of certain indices for which we had only a few patients. For instance, only two patients were in Grade 4 of the Ability Index, only five in Class IV of the NYHA functional class, and five in Class 5 of the CHDFI, even though our distributions are in line with those reported in prior research^{16, 33}.

Future research should determine whether these classifications, and specifically the CHDFI, are reliable when several different healthcare professionals are assessing the patients. Further, the newly developed AP-classification²⁹ should be added in this list of scales to be further scrutinized in future research, as it shows similar characteristics to the CHDFI and may therefore also have a predictive value for long-term mortality despite being designed for other purposes.

Conclusions

Four of the five tools showed significant capability to predict 15 year mortality in adult patients with CHD. The predictive value of the CHDFI showed more robustness of the model

as compared to the other scales. The predictive value of the CHDFI showed more robustness of the model when compared to the other scales and emphasizes the importance to include functional/physiological variables to encompass the fluctuations in the patient's health status. Future research needs to validate the ACHD Anatomic and Physiological classification, as proposed by the 2018 AHA/ACC guidelines²⁹, and future psychometric evaluations and research in larger samples should determine its usability to detect patients at risk for mortality or morbidity. Additional research should verify its capacity to determine probabilities for no cardiac events occurring in the long term to determine whether this scale is truly superior.

Acknowledgments

Not applicable

Funding Sources

This work was supported by Research Foundation Flanders [G097516N to PM and 12E9816N to EG].

Disclosures

None

References

1. Diller GP, Kempny A, Alonso-Gonzalez R, et al. Survival Prospects and Circumstances of Death in Contemporary Adult Congenital Heart Disease Patients Under Follow-Up at a Large Tertiary Centre. *Circulation* 2015;132:2118-25.
2. Joshi SS, Anthony G, Manasa D, et al. Predicting mortality after congenital heart surgeries: evaluation of the Aristotle and Risk Adjustment in Congenital Heart Surgery-1 risk prediction scoring systems: a retrospective single center analysis of 1150 patients. *Ann Card Anaesth* 2014;17:266-70.
3. Best KE, Tennant PWG, Rankin J. Survival, by Birth Weight and Gestational Age, in Individuals With Congenital Heart Disease: A Population-Based Study. *J Am Heart Assoc* 2017;6.
4. Berger JT, Holubkov R, Reeder R, et al. Morbidity and mortality prediction in pediatric heart surgery: Physiological profiles and surgical complexity. *J Thorac Cardiovasc Surg* 2017;154:620-8.e6.
5. Alsaied T, Bokma JP, Engel ME, et al. Factors associated with long-term mortality after Fontan procedures: a systematic review. *Heart* 2017;103:104-10.
6. Almond CS, Gauvreau K, Canter CE, Rajagopal SK, Piercey GE, Singh TP. A risk-prediction model for in-hospital mortality after heart transplantation in US children. *Am J Transplant* 2012;12:1240-8.
7. Baggen VJM, Venema E, Zivna R, et al. Development and validation of a risk prediction model in patients with adult congenital heart disease. *Int J Cardiol* 2018.
8. Warnes CA, Liberthson R, Danielson GK, et al. Task force 1: the changing profile of congenital heart disease in adult life. *J Am Coll Cardiol* 2001;37:1170-5.
9. Arslani K, Roffler N, Zurek M, et al. Patterns of Incidence Rates of Cardiac Complications in Patients With Congenital Heart Disease. *Can J Cardiol* 2018;34:1624-30.
10. New York Heart Association. The criteria committee of the New York Heart Association, functional capacity and objective assessment. *Nomenclature and criteria for diagnosis of diseases of the heart and great vessels*: Little Brown and Company, Boston, MA; 1994:253-5.
11. Warnes CA, Somerville J. Tricuspid atresia in adolescents and adults: current state and late complications. *Br Heart J* 1986;56:535-43.
12. Miller MR, Forrest CB, Kan JS. Parental preferences for primary and specialty care collaboration in the management of teenagers with congenital heart disease. *Pediatrics* 2000;106:264-9.
13. Moons P, Van Deyk K, De Geest S, Gewillig M, Budts W. Is the severity of congenital heart disease associated with the quality of life and perceived health of adult patients? *Heart* 2005;91:1193-8.
14. Oliver JM, Gallego P, Gonzalez AE, et al. Risk factors for excess mortality in adults with congenital heart diseases. *Eur Heart J* 2017;38:1233-41.
15. van der Bom T, Mulder BJ, Meijboom FJ, et al. Contemporary survival of adults with congenital heart disease. *Heart* 2015;101:1989-95.
16. Bredy C, Ministeri M, Kempny A, et al. New York Heart Association (NYHA) classification in adults with congenital heart disease: relation to objective measures of exercise and outcome. *Eur Heart J Qual Care Clin Outcomes* 2018;4:51-8.
17. Moons P, Van Deyk K, Marquet K, et al. Individual quality of life in adults with congenital heart disease: a paradigm shift. *Eur Heart J* 2005;26:298-307.
18. Moons P, Van Deyk K, De Bleser L, et al. Quality of life and health status in adults with congenital heart disease: a direct comparison with healthy counterparts. *Eur J Cardiovasc Prev Rehabil* 2006;13:407-13.
19. Mitchell SC, Korones SB, Berendes HW. Congenital heart disease in 56,109 births. Incidence and natural history. *Circulation* 1971;43:323-32.

20. Hicks KA, Tcheng JE, Bozkurt B, et al. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials. *J Am Coll Cardiol* 2015;66:403-69.
21. Harrell FE, Jr., Lee KL, Califf RM, Pryor DB, Rosati RA. Regression modelling strategies for improved prognostic prediction. *Stat Med* 1984;3:143-52.
22. Hosmer DW, Lemeshow S. *Applied Logistic Regression*. New York, NY: John Wiley & Sons; 2000.
23. Kang L, Chen W, Petrick NA, Gallas BD. Comparing two correlated C indices with right-censored survival outcome: a one-shot nonparametric approach. *Stat Med* 2015;34:685-703.
24. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing 2017.
25. Engelings CC, Helm PC, Abdul-Khaliq H, et al. Cause of death in adults with congenital heart disease - An analysis of the German National Register for Congenital Heart Defects. *Int J Cardiol* 2016;211:31-6.
26. Tutarel O, Kempny A, Alonso-Gonzalez R, et al. Congenital heart disease beyond the age of 60: emergence of a new population with high resource utilization, high morbidity, and high mortality. *Eur Heart J* 2014;35:725-32.
27. Verheugt CL, Uiterwaal CS, van der Velde ET, et al. Mortality in adult congenital heart disease. *Eur Heart J* 2010;31:1220-9.
28. Gallego P, Gonzalez AE, Sanchez-Recalde A, et al. Incidence and predictors of sudden cardiac arrest in adults with congenital heart defects repaired before adult life. *Am J Cardiol* 2012;110:109-17.
29. Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation* 2019;139:e698-e800.
30. Mackie AS, Tran DT, Marelli AJ, Kaul P. Cost of Congenital Heart Disease Hospitalizations in Canada: A Population-Based Study. *Can J Cardiol* 2017;33:792-8.
31. Budts W. Individual risk stratification in adult congenital heart disease: the way to go? *Eur Heart J* 2017;38:1242-4.
32. Moons P, Bovijn L, Budts W, Belmans A, Gewillig M. Temporal trends in survival to adulthood among patients born with congenital heart disease from 1970 to 1992 in Belgium. *Circulation* 2010;122:2264-72.
33. Norozi K, Wessel A, Buchhorn R, et al. Is the Ability index superior to the NYHA classification for assessing heart failure?: comparison of two classification scales in adolescents and adults with operated congenital heart defects. *Clin Res Cardiol* 2007;96:542-7.

Figure legends

FIGURE 1: Distribution of included patients' scores on the five indices, probability for all-cause and cardiac mortality over at 15 years

Legend: NYHA= New York Heart Association Functional Class, CHDFI= Congenital Heart Disease Functional Index

FIGURE 2 Kaplan Meier curves for all-cause and cardiac mortality for the five functional indices.

Legend: NYHA= New York Heart Association Functional Class, CHDFI= Congenital Heart Disease Functional Index

TABLE 1: Demographic and Clinical Characteristics of 629 Adults with Congenital Heart Disease at Time of Inclusion

Variable	n (%)
Median age (y) at inclusion	24 (IQR 20-29)
Men	378 (60)
Marital status	
Unmarried living with parents	346 (55)
Unmarried living alone	50 (8)
Living together	81 (13)
Married	139 (22)
Divorced	9 (1)
Widow(er)	1 (0.2)
Primary diagnosis for type of heart defect	
Tetralogy of Fallot	112 (18)
Ventricular septal defect	108 (17)
Coarctation of the Aorta	89 (14)
Aortic valve stenosis	65 (10)
Pulmonary valve stenosis	48 (8)
Transposition of the Great Arteries (with atrial switch)	33 (5)
Transposition of the Great Arteries (with arterial switch)	1 (0.2)
Transposition of the Great Arteries (Rastelli or Blalock-Hanlon)	2 (0.3)
Mixed aortic valve disease	28 (4)

Atrial septal defect type 2	23 (4)
Mitral valve insufficiency	20 (3)
Univentricular heart	18 (3)
Double outlet right ventricle	12 (2)
Congenitally corrected transposition of the great arteries	11 (1)
Ebstein malformation of the tricuspid valve	9 (1)
Aortic valve insufficiency	8 (1)
Atrial septal defect type 1	8 (1)
Other	35 (6)
History of intervention	
No intervention	202 (32)
Surgery	330 (52)
Catheter intervention	28 (4)
Both surgical and catheter interventions	69 (11)
Genetic syndrome associated with congenital heart disease	26 (4)

TABLE 2: Harrell's C-index of disease severity and functional indices

	All-cause mortality	Cardiac mortality
	C-index* (95% CI)	C-index* (95% CI)
Bethesda Classification	0.67 (0.59-0.75)	0.67 (0.57-0.77)
NYHA	0.71 (0.65-0.77)	0.65 (0.58-0.73)
Ability Index	0.69 (0.63-0.74)	0.64 (0.57-0.71)
Disease Severity Index	0.58 (0.50-0.65)	0.55 (0.46-0.64)
CHDFI	0.74 (0.66-0.82)	0.76 (0.66-0.86)

Legend: C-index: concordance statistics index; 99.7% CI = 99.7% Confidence interval; NYHA = New York Heart Association; CHDFI = Congenital Heart Disease Functional Index. * C-Index <0.70 is a poor model; C-Index 0.70-0.79 is a good model; C-Index 0.80-0.89 is an excellent model; C-Index ≥ 0.90 is an outstanding model.

Figures

FIGURE 1: Distribution of included patients' scores on the five indices, probability for all-cause and cardiac mortality at 15 years

Legend: NYHA= New York Heart Association Functional Class, CHDFI= Congenital Heart Disease Functional Index

FIGURE 2 Kaplan Meier curves for all-cause and cardiac mortality for the five functional indices.

Legend: NYHA= New York Heart Association Functional Class, CHDFI= Congenital Heart Disease Functional Index